Cooper Companies vs Dentsply Sirona
Add, change or remove companies; up to four.
The short version
- Cooper Companies is the larger business, with $4.1B of revenue in fiscal 2025 against $3.7B for Dentsply Sirona.
- Cooper Companies grew revenue faster (5.1%, against −3.0%).
- Cooper Companies kept more of each dollar of sales as operating profit (16.7% operating margin, against −11.5%).
- Cooper Companies turned more of its sales into free cash flow (10.6% FCF margin, against 2.8%).
- Cooper Companies earned a higher return on the capital invested in it (4.3%, against −9.9%).
| Latest fiscal year | COO · FY25 | XRAY · FY25 |
|---|---|---|
| Size | ||
| Market cap | $11.8B | $1.9B |
| Revenue | $4.1B | $3.7B |
| Free cash flow | $434M | $104M |
| Net income | $375M | −$598M |
| Growth | ||
| Revenue growth | 5.1% | −3.0% |
| 5-year growth | 11.0% | 2.0% |
| Share count change | −0.2% | −1.9% |
| Profitability | ||
| Gross margin | 65.5% | 50.0% |
| Operating margin | 16.7% | −11.5% |
| Net margin | 9.2% | −16.3% |
| FCF margin | 10.6% | 2.8% |
| Return on capital | 4.3% | −9.9% |
| Return on equity | 4.6% | −36.5% |
| Balance sheet | ||
| Net debt | $2.4B | $2.0B |
| Net debt / EBITDA | 2.3x | — |
| Dividends and buybacks | $290M | $128M |
| Valuation & quality | ||
| P/E | 21.0x | — |
| Piotroski F-score | 5 | 6 |
Revenue
FY16
COO $2.0B
XRAY $0.0M
FY17
COO $2.1B
XRAY $4.0B
FY18
COO $2.5B
XRAY $4.0B
FY19
COO $2.7B
XRAY $4.0B
FY20
COO $2.4B
XRAY $3.3B
FY21
COO $2.9B
XRAY $4.2B
FY22
COO $3.3B
XRAY $3.9B
FY23
COO $3.6B
XRAY $4.0B
FY24
COO $3.9B
XRAY $3.8B
FY25
COO $4.1B
XRAY $3.7B
COO
XRAY
Operating margin
FY16
COO 16.5%
XRAY —
FY17
COO 20.1%
XRAY −39.1%
FY18
COO 15.9%
XRAY −24.0%
FY19
COO 20.6%
XRAY 8.8%
FY20
COO 12.8%
XRAY −0.1%
FY21
COO 17.3%
XRAY 14.4%
FY22
COO 15.3%
XRAY −23.9%
FY23
COO 14.8%
XRAY −2.1%
FY24
COO 18.1%
XRAY −23.2%
FY25
COO 16.7%
XRAY −11.5%
COO
XRAY
Free cash flow
FY16
COO $357M
XRAY $438M
FY17
COO $466M
XRAY $458M
FY18
COO $475M
XRAY $317M
FY19
COO $421M
XRAY $516M
FY20
COO $176M
XRAY $562M
FY21
COO $524M
XRAY $515M
FY22
COO $450M
XRAY $368M
FY23
COO $215M
XRAY $228M
FY24
COO $288M
XRAY $281M
FY25
COO $434M
XRAY $104M
COO
XRAY
Return on capital
FY16
COO 7.4%
XRAY 7.1%
FY17
COO 9.7%
XRAY −14.4%
FY18
COO 4.2%
XRAY −10.6%
FY19
COO 10.6%
XRAY 4.3%
FY20
COO 5.6%
XRAY −0.0%
FY21
COO 7.6%
XRAY 6.9%
FY22
COO 4.6%
XRAY −12.4%
FY23
COO 3.8%
XRAY −1.3%
FY24
COO 4.6%
XRAY −16.8%
FY25
COO 4.3%
XRAY −9.9%
COO
XRAY
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.